HC Wainwright & Co. analyst Edward White downgrades Vyant Bio (NASDAQ:VYNT) from Buy to Neutral.
Mizuho Maintains Neutral on Neurocrine Biosciences, Maintains $116 Price Target
Mizuho analyst Uy Ear maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Neutral and maintains $116 price target.